Skip to main
SNTI

SNTI Stock Forecast & Price Target

SNTI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Senti Biosciences is a clinical-stage biotechnology company developing cell and gene therapies for patients with incurable diseases. With promising results from its lead candidate, SENTI-202, in a Phase 1 clinical trial for relapsed/refractory AML and recently receiving RMAT designation, the company is well-positioned for future success. However, potential cash runway issues and anticipated dilution remain as concerns to be addressed.

Bears say

Senti Biosciences is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. The company has a novel gene circuit platform that is designed to reprogram cells to sense, compute, and respond to cellular environments. However, there are several key risks to the company's success, including the potential for unanticipated toxicities in its clinical trials, competition from other players in the cell therapy space, and potential manufacturing challenges. These risks could impact the company's ability to achieve its target sales and lead to downward revisions in its valuation. In addition, the company has a limited cash runway and may need to raise additional capital, leading to potential shareholder dilution. Therefore, as a financial analyst, I have a negative outlook on Senti Biosciences's stock.

SNTI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Senti Biosciences Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Senti Biosciences Holdings Inc (SNTI) Forecast

Analysts have given SNTI a Strong Buy based on their latest research and market trends.

According to 4 analysts, SNTI has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Senti Biosciences Holdings Inc (SNTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.